DiaMedica Therapeutics Inc. financial data

Symbol
DMAC on Nasdaq
Industry
Pharmaceutical Preparations
Location
301 Carlson Parkway, Suite 210, Minneapolis, Minnesota
State of incorporation
Canada (Federal Level)
Fiscal year end
December 31
Former names
DiaMedica Inc. (to 3/11/2014)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2 K % +15.8%
Return On Equity -36.2 % +22.8%
Return On Assets -34.5 % +21.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 38 M shares +43.5%
Common Stock, Shares, Outstanding 38 M shares +43.5%
Entity Public Float 103 M USD +96.2%
Common Stock, Value, Issued 0 USD
Weighted Average Number of Shares Outstanding, Basic 38 M shares +43.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 13.2 M USD +38.9%
General and Administrative Expense 8.32 M USD +27.9%
Operating Income (Loss) -21.5 M USD -34.4%
Nonoperating Income (Expense) 1.93 M USD +446%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -19.2 M USD -24.7%
Income Tax Expense (Benefit) 43 K USD +53.6%
Net Income (Loss) Attributable to Parent -19.3 M USD -24.7%
Earnings Per Share, Basic -0.54 USD/shares +8.48%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.1 M USD -2.33%
Marketable Securities, Current 44.4 M USD +67.6%
Cash, Cash Equivalents, and Short-term Investments 46.5 M USD +62%
Accounts Receivable, after Allowance for Credit Loss, Current 399 K USD +600%
Assets, Current 47.5 M USD +60%
Property, Plant and Equipment, Net 132 K USD -2.94%
Operating Lease, Right-of-Use Asset 336 K USD -17.4%
Assets 49.3 M USD +63%
Accounts Payable, Current 716 K USD -59.8%
Employee-related Liabilities, Current 317 K USD +96.9%
Accrued Liabilities, Current 1.82 M USD +89.9%
Liabilities, Current 2.62 M USD -7%
Operating Lease, Liability, Noncurrent 294 K USD +7250%
Accumulated Other Comprehensive Income (Loss), Net of Tax -39 K USD -34.5%
Retained Earnings (Accumulated Deficit) -121 M USD -19%
Stockholders' Equity Attributable to Parent 46.3 M USD +71.5%
Liabilities and Equity 49.3 M USD +63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.65 M USD -30.7%
Net Cash Provided by (Used in) Financing Activities 36.8 M USD
Net Cash Provided by (Used in) Investing Activities 4.21 M USD +67.7%
Common Stock, Shares, Issued 38 M shares +43.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.45 M USD +5.23%
Deferred Tax Assets, Valuation Allowance 28 M USD +23.3%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.27 pure 0%
Operating Lease, Liability 377 K USD -16.2%
Depreciation 8 K USD +14.3%
Payments to Acquire Property, Plant, and Equipment 9 K USD +28.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -19.3 M USD -25.4%
Lessee, Operating Lease, Liability, to be Paid 440 K USD -19.6%
Property, Plant and Equipment, Gross 238 K USD +8.68%
Operating Lease, Liability, Current 83 K USD +1560%
Lessee, Operating Lease, Liability, to be Paid, Year Two 116 K USD +2.66%
Lessee, Operating Lease, Liability, to be Paid, Year One 113 K USD +3.67%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 63 K USD -35.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 119 K USD +2.59%
Deferred Tax Assets, Operating Loss Carryforwards 26 M USD +24%
Lessee, Operating Lease, Liability, to be Paid, Year Four 10 K USD -91.6%
Additional Paid in Capital 167 M USD +30%
Deferred Tax Assets, Net of Valuation Allowance 28 M USD +23.3%
Share-based Payment Arrangement, Expense 1.75 M USD +8.23%